Minerva Neurosciences Inc logo

NERV

Minerva Neurosciences Inc

$3.66

Earnings Summary

Revenue
$0Mn
Net Profits
$-9.76Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Minerva Neurosciences Inc’s revenue fell -100% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Minerva Neurosciences Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Minerva Neurosciences Inc’s net profit fell -10.9% since last year same period to $-9.76Mn in the Q1 2022. On a quarterly growth basis, Minerva Neurosciences Inc has generated 54.17% jump in its net profits since last 3-months.

Net Profit Margins:

Minerva Neurosciences Inc’s net profit margin fell -Inf% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Minerva Neurosciences Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Minerva Neurosciences Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.65
EPS Estimate Current Year
-1.65

Highlights

EPS Estimate Current Quarter:

Minerva Neurosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -1.65 - a -11.49% fall from last quarter’s estimates.

EPS Estimate Current Year:

Minerva Neurosciences Inc’s earning per share (EPS) estimates for the current year stand at -1.65.

Key Ratios

Key ratios of the Minerva Neurosciences Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-1.84
Return on Assets (ROA)
-0.21
Return on Equity (ROE)
-3.53
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Minerva Neurosciences Inc’s earning per share (EPS) fell -9.52% since last year same period to -1.84 in the Q1 2022. This indicates that the Minerva Neurosciences Inc has generated -9.52% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Minerva Neurosciences Inc’s return on assets (ROA) stands at -0.21.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Minerva Neurosciences Inc’s return on equity (ROE) stands at -3.53.

Dividend Per Share (DPS):

Minerva Neurosciences Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
-1.48
-1.84
-24.32%

Company Information

Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.

Organisation
Minerva Neurosciences Inc
Headquarters
Waltham, Massachusetts, US
Employees
11
Industry
Health Technology
CEO
Remy Luthringer